Surrozen Inc. Warrant

Surrozen, Inc. is a biotechnology company that discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead candidates are antibody-based therapeutics targeting diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company is developing SZN-814, SZN-8143, and SZN-413 for retinal and other indications. It has a collaboration and license agreement with Boehringer Ingelheim International GmbH and a research collaboration with TCGFB, Inc. Founded in 2015, Surrozen is headquartered in South San Francisco, California.